WallStreetZenWallStreetZen

NASDAQ: ICCC
Immucell Corp Earnings & Revenue

OverviewEarnings
DividendOwnership

ICCC past revenue growth

How has ICCC's revenue growth performed historically?
Company
-5.9%
Industry
149.3%
Market
17.29%
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ICCC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ICCC's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ICCC earnings and revenue history

Current Revenue
$17.5M
Current Earnings
-$5.8M
Current Profit Margin
-33.1%

ICCC Return on Equity

Current Company
-21.8%
Current Industry
-63.5%
Current Market
188%
ICCC's Return on Equity (-21.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ICCC announces earnings.

ICCC Return on Assets

Current Company
-13.2%
Current Industry
2.9%
ICCC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ICCC Return on Capital Employed

Current Company
-14.57%
Current Industry
19.5%
ICCC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ICCC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ICCC$17.47M-$3.05M-$5.77M+9.72%N/A
ESLA$0.00-$8.36M-$8.36MN/AN/A
PMN$0.00-$12.99M-$13.21MN/AN/A
MTNB$1.10M-$22.00M-$22.94M+476.30%N/A
CTCX$0.00-$14.47M-$16.12MN/AN/A
View Top Biotech Stocks

ICCC earnings dates

Next earnings date
May 10, 2024

Immucell Earnings & Revenue FAQ

What were ICCC's earnings last quarter?

On Invalid Date, Immucell (NASDAQ: ICCC) reported Q4 2023 earnings per share (EPS) of -$0.15, up 28.57% year over year. Total Immucell earnings for the quarter were -$1.14 million. In the same quarter last year, Immucell's earnings per share (EPS) was -$0.21.

If you're new to stock investing, here's how to buy Immucell stock.

What was ICCC's earnings growth in the past year?

As of Q2 2024, Immucell's earnings has grown year over year. Immucell's earnings in the past year totalled -$5.77 million.

What is ICCC's earnings date?

Immucell's earnings date is Invalid Date. Add ICCC to your watchlist to be reminded of ICCC's next earnings announcement.

What was ICCC's revenue last quarter?

On Invalid Date, Immucell (NASDAQ: ICCC) reported Q4 2023 revenue of $5.10 million up 30.3% year over year. In the same quarter last year, Immucell's revenue was $3.91 million.

What was ICCC's revenue growth in the past year?

As of Q2 2024, Immucell's revenue has grown -5.9% year over year. This is 155.2 percentage points lower than the US Biotechnology industry revenue growth rate of 149.3%. Immucell's revenue in the past year totalled $17.47 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.